N/A N=391 Investigating Superion™ In Spinal Stenosis
Lumbar Spinal Stenosis · Intermittent Claudication
Primary: Percentage of Subjects With Clinically Significant Improvement in Outcomes — 52.7; 50.2 percentage of subjects
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=229 Clinical Investigation of the Next-Generation Intraocular Lens
Cataract
Primary: Monocular Distance Corrected Near Visual Acuity (DCNVA) at 40 cm — 0.136; 0.141; 0.276 LogMAR
Phase 3 N=223 Analysis of 18F-AV-1451 PET Imaging in Cognitively Healthy, MCI, and AD Subjects
Alzheimer's Disease
Primary: Confirmatory Phase: Relationship Between Neocortical Flortaucipir Uptake and the Subsequent Rate of Cognitive Decline — 36; 31; 27; 37 Participants — p=0.067
N/A N=225 Instant Total Contact Cast to Heal Diabetic Foot Ulcers
Diabetic Foot Ulcers
Primary: Number of Participants Who Achieve Full Wound Healing. — 35; 63; 37 Participants
Phase 4 N=47 Metformin and Its Impact on the Substances Associated With NO Production in Prediabetes Patients.
PreDiabetes · Impaired Fasting Glucose (IFG) · Impaired Glucose Tolerance (IGT)
Primary: Serum Levels of Metformin at Different Time Points — 4.36; 4.25; 5.09; 7.42 µM
Phase 4 N=310 Effects of Bupivacaine Induced Motor Blockade During the Second Stage of Labor
Pregnancy
Primary: The Duration of the Second Stage of Labor — 75; 73 minutes — p=0.17
N/A N=211 Cook Enforcer Post-Market Study
End-Stage Renal Disease
Primary: Percent of Lesions Requiring Adjunctive Treatment — 30; 26 Lesions — p=0.8283
Phase 2 N=34 Brentuximab Vedotin Plus AD in Non-bulky Limited Stage Hodgkin Lymphoma
Hodgkin Lymphoma
Primary: Complete Response Rate — 34 Participants
Phase 4 N=10 Renal Transplants in Hepatitis C Negative Recipients With Nucleic Acid Positive Donors
End Stage Renal Disease · Hepatitis C
Primary: Viral Response at Week 12 — 10 Participants
Phase 1 N=12 A Study of LY2835219 in Japanese Participants With Advanced Cancer
Neoplasm Metastasis · Lymphoma
Primary: Number of Participants With Abemaciclib Dose-Limiting Toxicity (DLT) — 0; 0; 1 Participants
N/A N=56 A Range of Contact Lenses and Care System Combinations
Contact Lens Solutions
Primary: Biomicroscopy - Conjuctival Hyperaemia — 0.95; 0.94; 0.91; 0.91 units on a scale
N/A N=150 Optimal Haloperidol Dose for Postoperative Nausea and Vomiting Prevention in High-risk Patients
Gynecological Disease
Primary: Incidence of Postoperative Nausea and Vomiting — 21; 11; 10 participants
Phase 2 N=22 Clinical Evaluation of Lyral® Dose Response Study
Contact Dermatitis
Primary: Number of Participants With Positive Patch Test Responses — 14; 12; 11; 0 participants
Phase 2 N=22 3D Augmented Reality Mirror Visual Feedback Applied to the Treatment of Unilateral Upper Extremity Neuropathic Pain.
Neuralgia
Primary: Pain on the Visual Analog Scale (VAS) — 6.4; 4.0 units on a scale
Phase 3 N=794 Tralokinumab Monotherapy for Moderate to Severe Atopic Dermatitis - ECZTRA 2 (ECZema TRAlokinumab Trial no. 2)
Atopic Dermatitis
Primary: Subjects With Investigator's Global Assessment (IGA) Score of 0 (Clear) or 1 (Almost Clear) at Week 16. — 131; 22 Participants — p=<0.001